2017
DOI: 10.1016/j.joca.2016.12.025
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: This study demonstrated the efficacy of duloxetine in Chinese patients with chronic pain due to OA. The safety profile of duloxetine observed in this study was consistent with that in previous duloxetine trials. This trial is registered with ClinicalTrials.gov (NCT01931475).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
64
4

Year Published

2018
2018
2019
2019

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 45 publications
(19 citation statements)
references
References 22 publications
(19 reference statements)
4
64
4
Order By: Relevance
“…There were few differences in treatment regimen among the studies, with the duration ranging from 10 to 16 weeks. In one study, the participants had OA in either the knee or hip; however, for most patients (404/407, 99.3%), the affected joint was the knee . Besides the primary outcomes, which included chronic pain, joint stiffness, and physical function, reported in each study, five studies also reported TEAE, serious AE, and discontinuations.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…There were few differences in treatment regimen among the studies, with the duration ranging from 10 to 16 weeks. In one study, the participants had OA in either the knee or hip; however, for most patients (404/407, 99.3%), the affected joint was the knee . Besides the primary outcomes, which included chronic pain, joint stiffness, and physical function, reported in each study, five studies also reported TEAE, serious AE, and discontinuations.…”
Section: Resultsmentioning
confidence: 99%
“…With regard to randomisation and allocation concealment, one study 23 showed an unclear risk and the remaining five studies [20][21][22]24,25 all showed a low risk. Furthermore, all six studies appeared to be at low risk with regard to blindness, incomplete outcome data, and selective reporting, but they were unclear for other biases.…”
Section: Quality Assessmentmentioning
confidence: 99%
“…More recently, duloxetine-a centrally acting serotonin norepinephrine reuptake inhibitor-has been approved as an alternative means for treating OA pain. Multiple large multicenter RCTs in patients with knee OA, and meta-analysis of such studies, show that daily duloxetine (60/ 120 mg) in comparison to placebo results in a greater reduction in pain, improved function, and a patient-rated impression of improvement after 10-13 weeks of treatment (Chappell et al, 2009;Wang et al, 2015Wang et al, , 2016. Managing OA pain with centrally acting drugs is consistent with evidence demonstrating central abnormalities associated with OA (Baliki et al, 2008;Baliki, Schnitzer, Bauer, & Apkarian, 2011;Baliki, Mansour, Baria, & Apkarian, 2014;Gwilym, Filippini, Douaud, Carr, & Tracey, 2009;Hiramatsu et al, 2014;Parks et al, 2011).…”
Section: Dissemination Of Modern Pharmacotherapies Is Based On Clinicmentioning
confidence: 99%
“…The Osteoarthritis Research Society International (OARSI) guidelines recommend duloxetine as treatment for multiple‐joint OA with or without comorbidities . Some RCTs and meta‐analyses revealed the efficacy and safety of duloxetine for OA pain . Moreover, the SNRIs, including duloxetine, are regarded as the first therapeutic agents for neuropathic pain .…”
mentioning
confidence: 99%